A Phase 2 interventional study of Lu AG09222 and Placebo in Migraine, sponsored by H. Lundbeck A/S. Completed at 120 sites in 14 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by H. Lundbeck A/S · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Migraine Disorders by H. Lundbeck A/S — 3 open to participants now, 3 under way, 3 of them phase 3. Migraine Disorders · H. Lundbeck A/S.
Among the 23 studies in Migraine Disorders by H. Lundbeck A/S, this one is the 5th largest by enrollment, is one of 3 that started in 2024, is one of 3 in phase 2, and was the 21st registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →3 of the 23 studies in Migraine Disorders by H. Lundbeck A/S are open now, in 11 countries. Recruiting first, the newest first:
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 6–17
H. Lundbeck A/S · Sites in United States, Argentina, Canada and 8 more countries
Ages 12–17
By country, each count listing its studies:
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 874 is above the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 237 across the 23 interventional studies. Of the 20 that completed or were terminated, 9 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
2 of the studies in Migraine Disorders by H. Lundbeck A/S that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04965675Phase 3H. Lundbeck A/SA Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | 2027-03-26 |
| NCT05897320Phase 3H. Lundbeck A/SA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | 2027-07-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Migraine Disorders by H. Lundbeck A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.
Key Inclusion Criteria:
Key Exclusion Criteria:
Additional protocol-defined criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 2 injections of placebo.
Drug: Placebo
Participants will receive 1 injection of placebo and 1 injection containing Lu AG09222.
Drug: Lu AG09222 · Drug: Placebo
Participants will receive 1 injection of placebo and 1 injection containing Lu AG09222.
Drug: Lu AG09222 · Drug: Placebo
Participants will receive 1 injection of placebo and 1 injection containing Lu AG09222.
Drug: Lu AG09222 · Drug: Placebo
Participants will receive 2 injections, each containing Lu AG09222.
Drug: Lu AG09222
Participants will receive placebo by intravenous (IV) infusion.
Drug: Placebo
Participants will receive Lu AG09222 by IV infusion.
Drug: Lu AG09222
Participants will receive Lu AG09222 by IV infusion.
Drug: Lu AG09222
Participants will receive Lu AG09222 by IV infusion.
Drug: Lu AG09222
Lu AG09222 will be administered per the arm description.
Placebo matching to Lu AG09222 will be administered per the arm description
Change From Baseline in the Number of Monthly Migraine Days (MMDs)
Time frame: Baseline up to Week 12 (Weeks 1-12)
Change From Baseline in MMDs
Time frame: Baseline up to Week 12 (Weeks 1-12)
Percentage of Participants With ≥50% Reduction From Baseline in MMDs
Time frame: Baseline up to Week 12 (Weeks 1-12)
Percentage of Participants With ≥75% Reduction From Baseline in MMDs
Time frame: Baseline up to Week 12 (Weeks 1-12)
Change from Baseline in the Number of Monthly Headache Days
Time frame: Baseline up to Week 12 (Weeks 1-12)
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Time frame: Up to Week 20
Number of Participants with Anti-drug Antibodies (ADA)
Time frame: Up to Week 20
Showing the first 100 of 120 sites across 14 countries. Choose a country and city above to see the rest.
Ran from Apr 2024 to primary completion in Jan 2026, 21 months.
Of 43 industry-sponsored phase 2 interventional studies under Migraine Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 21 months is above that.
Counting every sponsor, half of 73 studies reached it within 15 months; a quarter within 11 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bocunebart